Search Results

You are looking at 41 - 50 of 791 items for :

  • "risk factor" x
  • Refine by Access: All x
Clear All
Full access

Hans Theodor Eich, Jan Kriz, and Rolf-Peter Müller

such as the definition of early-favorable, early-unfavorable, and advanced stages, and more specific, risk-adapted treatment strategies. Early-Favorable HL Extension of disease is still the most important risk factor. As reported by the Stanford

Full access

Manish A. Shah and David P. Kelsen

emerged in epidemiologic studies over the past several decades: gastric cardia/gastroesophageal junction (GEJ) tumors. 6 , 7 Table 1 provides a summary of commonly identified risk factors for the development of gastric cancer categorized by disease

Full access

Sarah T. Le, Pritesh S. Karia, Beverley J. Vollenhoven, Robert J. Besaw, Colleen M. Feltmate, and Chrysalyne D. Schmults

space invasion, margin distance, and clitoral involvement. 6 – 14 Due to inconsistent definitions and results across studies, most risk factors have not been adopted into current staging systems. The vulvar cancer staging system in the 8th edition of

Full access

Corbin D. Jacobs, Daniel J. Rocke, Russel R. Kahmke, Hannah Williamson, Gita Suneja, and Yvonne M. Mowery

-defined risk factors (positive margin, lymphovascular invasion, pT3–4, N2–3, extranodal extension, or level IV/V nodal metastasis), and unknown/missing NCCN risk factor data. Log-rank test stratified by RT and Cox regression analyses with respect to OS were

Full access

Nirmala K. Manjappachar, John A. Cuenca, Claudia M. Ramírez, Mike Hernandez, Peyton Martin, Maria P. Reyes, Alba J. Heatter, Cristina Gutierrez, Nisha Rathi, Charles L. Sprung, Kristen J. Price, and Joseph L. Nates

; APL, acute promyelocytic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; GVHD, graft-versus-host disease; MM, multiple myeloma. Figure 3. Multivariable analysis of risk factors associated with 28-day mortality (n=456

Full access

Therese B. Bevers, Deborah K. Armstrong, Banu Arun, Robert W. Carlson, Kenneth H. Cowan, Mary B. Daly, Irvin Fleming, Judy E. Garber, Mary Gemignani, William J. Gradishar, Helen Krontiras, Swati Kulkarni, Christine Laronga, Loretta Loftus, Deborah J. MacDonald, Martin C. Mahoney, Sofia D. Merajver, Ingrid Meszoely, Lisa Newman, Elizabeth Pritchard, Victoria Seewaldt, Rena V. Sellin, Charles L. Shapiro, and John H. Ward

the United States in 2010. 1 Risk factors for the development of breast cancer can be grouped into categories, including familial/genetic factors (family history, known or suspected BRCA1/2, TP53, PTEN , or other gene mutation associated with breast

Full access

Presenters: Valencia D. Thomas, Michael K. Wong, and Andrew J. Bishop

, provide an outline for patient stratification based on risk factors for local recurrence, metastases, and death from disease ( Figure 1 ). 2 “There are so many characteristics and elements that we must take into consideration that there are conflicting

Full access

Jeffrey Crawford, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A. Griffiths, Shannon Hough, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Vivek Roy, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L. Burns, and Lenora Pluchino

-Hodgkin's lymphoma (NHL) has shown that the rates of myelosuppression and delivered dose intensity are underreported. 4 Due to individual patient risk factors, the rates of myelosuppression with the same or similar regimens varied greatly, making it difficult to

Full access

Anne M. Covey

have a known risk factor, 11 and we believe that implementing screening programs for those known populations improves OS. Other risk factors in the setting of HCV cirrhosis include male sex, coinfection with HIV or HBV, older age, diabetes, and obesity

Full access

Jeffrey Crawford and George M. Rodgers

resistant bacteria, and do not impact the depth and duration of neutropenia, which is the major risk factor for FN. Risk Assessment Per NCCN Guidelines Before the start of chemotherapy, patients should be evaluated for their risk of FN based on